MX2018011679A - Biomarcadores de proteopatias y usos de los mismos. - Google Patents
Biomarcadores de proteopatias y usos de los mismos.Info
- Publication number
- MX2018011679A MX2018011679A MX2018011679A MX2018011679A MX2018011679A MX 2018011679 A MX2018011679 A MX 2018011679A MX 2018011679 A MX2018011679 A MX 2018011679A MX 2018011679 A MX2018011679 A MX 2018011679A MX 2018011679 A MX2018011679 A MX 2018011679A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- proteopathy
- determining
- proteopathies
- biomarkers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
En la presente se proporcionan métodos para determinar la eficacia de un tratamiento para una proteopatía, diagnosticar una proteopatía en un sujeto, determinar si un sujeto está en riesgo de desarrollar una proteopatía, determinar la etapa de una proteopatía en un sujeto, monitorear una proteopatía en un sujeto, seleccionar un tratamiento para una proteopatía para un sujeto y seleccionar un sujeto para un ensayo clínico que incluye determinar un nivel de al menos un esfingolipido en una muestra que incluye un fluido biológico del sujeto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662313638P | 2016-03-25 | 2016-03-25 | |
US201662372523P | 2016-08-09 | 2016-08-09 | |
PCT/US2017/024012 WO2017165766A2 (en) | 2016-03-25 | 2017-03-24 | Biomarkers of proteopathies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018011679A true MX2018011679A (es) | 2019-06-24 |
Family
ID=58547821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018011679A MX2018011679A (es) | 2016-03-25 | 2017-03-24 | Biomarcadores de proteopatias y usos de los mismos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200124624A1 (es) |
EP (1) | EP3433623A2 (es) |
JP (2) | JP6940515B2 (es) |
KR (1) | KR20180124971A (es) |
AU (1) | AU2017238769A1 (es) |
CA (1) | CA3018745A1 (es) |
IL (1) | IL261906A (es) |
MA (1) | MA44484A (es) |
MX (1) | MX2018011679A (es) |
WO (1) | WO2017165766A2 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230201136A1 (en) * | 2020-02-28 | 2023-06-29 | Genemo, Inc. | Methods and materials for diagnosis and treatment of neuronal disorder |
CN112798727B (zh) * | 2021-04-09 | 2021-07-06 | 宝枫生物科技(北京)有限公司 | 用于诊断脑白质病变的生物标志物f7及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8781557B2 (en) | 1999-08-11 | 2014-07-15 | Osteoplastics, Llc | Producing a three dimensional model of an implant |
AU2001269923A1 (en) * | 2000-06-19 | 2002-01-02 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
CA2555989A1 (en) | 2004-02-24 | 2005-09-01 | Innogenetics N.V. | Method for determining the risk of developing a neurological disease |
GB2414309B (en) | 2004-05-18 | 2009-02-25 | Simon Richard Daniel | Spherical display and control device |
EP3284469B1 (en) | 2006-09-12 | 2020-11-04 | Genzyme Corporation | Compositions and methods for detection of lysosomal storage disease |
EP2594564B1 (en) | 2007-05-31 | 2016-09-28 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
US8026099B2 (en) | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
CN107935983A (zh) | 2008-10-03 | 2018-04-20 | 简詹姆公司 | 2‑酰胺基丙醇型葡糖神经酰胺合酶抑制剂 |
US20120052053A1 (en) * | 2008-11-14 | 2012-03-01 | Manning-Bog Amy B | Compositions and methods for the treatment of altered alpha-synuclein function |
CA2806302A1 (en) * | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting neurological or neuropsychiatric diseases or conditions |
MX365245B (es) * | 2011-03-18 | 2019-05-28 | Genzyme Corp | Inhibidores de glucosilceramida sintasa. |
JP6061922B2 (ja) * | 2011-06-22 | 2017-01-18 | ザ ジェネラル ホスピタル コーポレイション | プロテイノパチーの処置方法 |
EP2802670B1 (en) | 2011-11-08 | 2019-12-25 | University of Washington | Lysosomal enzyme assay methods and compositions |
-
2017
- 2017-03-24 JP JP2018549853A patent/JP6940515B2/ja active Active
- 2017-03-24 AU AU2017238769A patent/AU2017238769A1/en not_active Abandoned
- 2017-03-24 CA CA3018745A patent/CA3018745A1/en not_active Abandoned
- 2017-03-24 MX MX2018011679A patent/MX2018011679A/es unknown
- 2017-03-24 KR KR1020187030559A patent/KR20180124971A/ko unknown
- 2017-03-24 WO PCT/US2017/024012 patent/WO2017165766A2/en active Application Filing
- 2017-03-24 EP EP17717568.4A patent/EP3433623A2/en active Pending
- 2017-03-24 MA MA044484A patent/MA44484A/fr unknown
- 2017-03-24 US US16/088,031 patent/US20200124624A1/en active Pending
-
2018
- 2018-09-20 IL IL261906A patent/IL261906A/en unknown
-
2021
- 2021-09-02 JP JP2021142850A patent/JP7250081B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
MA44484A (fr) | 2019-01-30 |
JP7250081B2 (ja) | 2023-03-31 |
JP6940515B2 (ja) | 2021-09-29 |
WO2017165766A3 (en) | 2017-11-02 |
JP2019513231A (ja) | 2019-05-23 |
AU2017238769A1 (en) | 2018-11-15 |
EP3433623A2 (en) | 2019-01-30 |
IL261906A (en) | 2018-10-31 |
KR20180124971A (ko) | 2018-11-21 |
US20200124624A1 (en) | 2020-04-23 |
WO2017165766A2 (en) | 2017-09-28 |
JP2021185377A (ja) | 2021-12-09 |
CA3018745A1 (en) | 2017-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017070114A3 (en) | Diabetes-related biomarkers and treatment of diabetes-related conditions | |
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
EP3626832A3 (en) | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease | |
WO2013071119A3 (en) | Methods for treating, diagnosing and monitoring alzheimer's disease | |
MX2020001193A (es) | Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. | |
MX2021012347A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
MX2019002918A (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. | |
WO2015034886A3 (en) | Wellness panel for companion animals | |
BR112019005172A2 (pt) | método e kit para analisar uma amostra | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
MX2018011679A (es) | Biomarcadores de proteopatias y usos de los mismos. | |
WO2018022604A3 (en) | Methods of diagnosing and treating alzheimer's disease with s-equol | |
NZ751193A (en) | Protein biomarkers for diseases associated with the contact activation system | |
EP4328324A3 (en) | Methods of diagnosing epilepsy | |
MX2018006250A (es) | Biomarcador de enfermedad poliquistica renal y usos del mismo. | |
WO2015134791A3 (en) | Non-invasive biomarker of antibody-mediated allograft rejection | |
GB0713363D0 (en) | Diagnosis and treatment of abnormal blood conditions | |
UA109431U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA109433U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA109515U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA113364U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA108300U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA109299U (uk) | Спосіб діагностики розвитку остеопорозу | |
UA111396U (uk) | Спосіб діагностики розвитку остеопорозу |